Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)

This study tests orelabrutinib (a BTK inhibitor — a targeted therapy that blocks a protein that helps cancer cells grow) combined with standard chemotherapy regimens (BR or G) for patients with previously untreated marginal zone lymphoma, a slow-growing type of blood cancer. **You may be eligible if...** - You have newly confirmed marginal zone lymphoma (MALT, splenic, or nodal subtype) - Your cancer has progressed after local treatment or is not suitable for local treatment - You have signs that treatment is needed (symptoms, blood count problems, rapid tumor growth) - You are in acceptable physical condition (ECOG 0–3) - Your blood counts and organ function are adequate **You may NOT be eligible if...** - You have already received systemic treatment for marginal zone lymphoma - You have serious uncontrolled medical conditions - You are pregnant or breastfeeding - Your blood counts are below the required levels Talk to your doctor to see if this trial is right for you.